Sign in

    Gary Steventon

    Managing Director and Senior Equity Analyst at BNP Paribas Exane

    Gary Steventon is a Managing Director and Senior Equity Analyst at BNP Paribas Exane, specializing in European retail and consumer sectors with a particular focus on companies such as Kingfisher, Tesco, Carrefour, and Marks & Spencer. He is recognized for delivering actionable investment research, maintaining a reputation for high-quality stock recommendations with a strong track record evidenced by consistent top-tier analyst rankings and robust performance metrics, including a success rate above 60% and positive average returns on TipRanks. Steventon began his career in equity research in the late 2000s and, prior to BNP Paribas Exane, held analyst roles at leading finance firms including Merrill Lynch, building extensive expertise in retail equity coverage. He holds professional credentials such as FCA registration and the Investment Management Certificate, underscoring his commitment to regulatory standards and analytical excellence.

    Gary Steventon's questions to Sanofi (SNY) leadership

    Gary Steventon's questions to Sanofi (SNY) leadership • Q2 2024

    Question

    Gary Steventon asked about the moving parts in the Vaccines business that support its mid-single-digit growth outlook despite a weaker forecast for flu. He also inquired about the performance trends of Dupixent's approved indications relative to its EUR 13 billion target for the year.

    Answer

    Thomas Triomphe, EVP of Vaccines, explained that the outlook is supported by Beyfortus achieving blockbuster status and slight growth in endemic products, which offsets the low single-digit decline expected for the overall flu market. Brian Foard, EVP and Head of Global Hub, Specialty Care GBU, stated that Dupixent's performance is strong and demand-driven across all approved indications and geographies, which supports the confidence in reaching the EUR 13 billion target.

    Ask Fintool Equity Research AI